Skip to main content
. Author manuscript; available in PMC: 2021 Nov 15.
Published in final edited form as: Cell. 2020 Jun 10;181(7):1661–1679.e22. doi: 10.1016/j.cell.2020.05.001

Figure 7. MDM deglycosylation occurs in vivo.

Figure 7.

A) Schematic representation of the microbiome-dependent pharmacokinetic experiment performed here. B) Design of the capecitabine pharmacokinetic experiment. Mice are treated with antibiotics for 14 days, then colonized with PD (N=6) or left uncolonized (N=6). On the pharmacokinetic experiment day, a single human-equivalent dose is administered to mice using oral gavage, and serial sampling of blood (B) and feces (F) is performed at 0, 20, 40, 60, 120, and 240 minutes post dosing. C) HPLC-HRMS based quantification of deglycocapecitabine in fecal samples from mice colonized with PD in comparison to uncolonized ones. Metabolite AUC per gram of feces is normalized by the AUC of the internal standard (see STAR Methods). Error bars represent the standard error of the mean. The difference between the two conditions is significant (p < 0.01, determined by testing the intersection null hypothesis with marginal two-tailed t-tests using the Bonferroni correction to control family-wise error rate). See also Figure S7.